disease

Needham initiated coverage on MapLight Therapeutics Inc. (NASDAQ:MPLT). The company, which is focused on central nervous system disorders, debuted on NASDAQ in October 2025 and raised $296.3 million in IPO gross proceeds. • MapLight Therapeutics stock is showing positive momentum. What...

The U.S. Food and Drug Administration (FDA) on Friday approved Bristol Myers Squibb & Co.’s (NYSE:BMY) Opdivo (nivolumab) with chemotherapy for untreated Hodgkin lymphoma, one of the most curable forms of cancer, with high long-term survival rates, particularly when detected early...

Novartis AG (NYSE:NVS) on Friday agreed to acquire a next-generation PI3Kα inhibitor program from Synnovation Therapeutics, aiming to strengthen its breast cancer pipeline with a more targeted and potentially better-tolerated treatment approach. • Novartis stock is taking a breather. What...

Droplet Biosciences, a diagnostics company developing lymph-based liquid biopsy tests, announced on Tuesday a collaboration with NVIDIA Corp (NASDAQ:NVDA) to detect residual cancer within 24 hours of surgery — weeks earlier than traditional blood-based monitoring. By pairing lymphatic fluid...

The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE:BDX) new breast biopsy system. The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in early 2026. This...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Royalty Pharma plc (NASDAQ:RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408. IL-15 is a key cytokine involved in multiple immune-mediated...

Insmed Inc (NASDAQ:INSM) on Friday outlined a commercial and clinical roadmap for 2026, highlighting strong momentum from its respiratory portfolio and a series of upcoming trial readouts and launches that could shape the company's growth over the next 18 months. • Insmed stock is gaining...

Erasca Inc. (NASDAQ:ERAS) shares on Wednesday jumped close to 60% to $6.12. On Thursday, the stock fell as low as $4.33. • Erasca shares are advancing steadily. Why is ERAS stock trading higher? The movement came in reaction to a rumored deal, wherein AbbVie Inc. (NYSE:ABBV) was reportedly...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). • Bright Minds Biosciences stock...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are trading higher on Friday after the companies penned a merger deal. Today, BioMarin agreed to acquire Amicus Therapeutics for a total equity value of about $4.8 billion. • BioMarin Pharmaceutical...

The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE:MRK) drugs with potential blockbuster sales. Merck's cholesterol treatment enlicitide decanoate and cancer therapy sacituzumab tirumotecan (sac-TMT) have been reportedly...

Merck & Co. Inc. (NYSE:MRK) on Wednesday shared topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. • Merck & Co stock is showing upward bias. What’s...

Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY). The new agreement is built on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for...

Arcus Biosciences, Inc. (NYSE:RCUS) on Friday announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc. (NASDAQ:GILD), due to futility. • Arcus Biosciences stock is among today’s weakest performers. Why is RCUS stock dropping...

The National Medical Products Administration (NMPA) in China has approved Sanofi SA’s (NASDAQ:SNY) two medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura. • Sanofi stock is showing...